Transcript Slide 1
Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer By: Danielle Cervantes Thymidine Kinase Dot Blot Assay An analytical test that determines the specificity and selectivity of a medical test. Specificity Technique similar to Western Blotting that involves separating proteins by spotting through a circular template directly onto the cell membrane. Receiver Operating Characteristic A transferase enzyme that catalyzes phosphorylation of drugs into a form that will be active against viruses. Odds that a test will be negative in the absence of a disease Selectivity Odds that a test will be positive in the presence of a disease Non-Hodgkin's Lymphoma Is a class of cancers that affect the white blood cells Can be aggressive or indolent Estimated New Cases & Deaths in US in 2010 Cases: 65,540 Deaths: 21,210 cancer.osu.ed STK1 as a Prognostic Factor Used in prognosis after chemotherapy treatment Levels were determined by chemiluminescent dot-blot assay Before chemo, and 1 & 28 days after STK1 levels were analyzed two ways 1) Western blot using an anti-TK1 IgY antibody 2) Receiver Operating Characteristic (ROC) analysis STK1 as a Prognostic Factor Results Mean STK1 levels were much higher in patients with non-Hodgkin's lymphoma than in healthy people Levels decreased until at day 28 the level corresponded with that of a healthy person The mean of the STK1 levels was significantly correlated with the clinical response and 5-year survival rate Electrochemiluminescence (ECL) Assay labautopedia.or Designed to detect biological threats antigen complexes with 2 antibodies 1) attached to a magnetic particle 2) modified with a reporter molecule Electrode attracts magnetic particle and the detector emits light. Measured light is correlated with presence of antigen Complete Response (Complete Remission) Partial Response (Partial Remission) Cancer that is not increasing or decreasing in extent/severity Progressive Disease Decrease in size of tumor or extent of cancer after treatment Stable Disease Disappearance of all signs of cancer after treatment Cancer that's growing/spreading/getting worse Metastasis Process of cancer spreading from first location to another. Cancer resulting from the spread of the primary tumor STK1 in Cancer Treatment Experiment examined significance of STK1 in clinical settings Monitored 1,247 patients Concentration of STK1 was determined by ECL assay Value was correlated to clinical stage & reaction Monitored outcome of surgery/multi-drug chemo Looked at 5 different carcinomas Lung, esophagus, gastric, head & neck, & Results STK1 values correlated with clinical stage in 4 of 5 carcinomas Levels declined in all tumor groups after treatment In CR or PR patients levels decreased or were <2pM In SD or PD patients levels increased or were >2pM Some showed metastasis Overall STK1 correlates to clinical stages and reactions. It also monitors effectiveness of therapies in controlled/routine clinical trials Overall Results STK1 is a good indicator as to the presence of non-Hodgkin's lymphoma in patients STK1 is a good indicator of the effectiveness of treatment of different carcinomas It is not a good indicator of the effectiveness of treatment in head & neck carcinomas Significance of Results The results of these two studies show that levels of STK1 can be used as a prognostic and monitoring factor in cancer. This means that more invasive/expensive procedures can be omitted in treatment. References "Serum Thymidine Kinase 1 Correlates to Clinical Stages and Clinical Reactions and Monitors the Outcome of Therapy of 1,247 Cancer Patients in Routine Clinical Settings." http://www.cancer.gov http://www.antibodybeyond.com/applications/dotblot.htm "Electrochemiluminescence (ECL) Assay." <www.jpeocbd.osd.mil/packs/DocHandler.ashx?DocID=8597>. http://www.cancer.gov/cancertopics/types/non-hodgkin "Serum Thymidine Kinase 1 Concentration as a Prognostic Factor of Chemotherapy-treated Non-Hodgkin's Lymphoma Patients." http://www.medcalc.be/manual/roc.php